Effects of Insulin-Like Growth Factor (IGF)-I/IGF-Binding Protein-3 Treatment on Glucose Metabolism and Fat Distribution in Human Immunodeficiency Virus-Infected Patients with Abdominal Obesity and Insulin Resistance
Author(s) -
Madhu N. Rao,
Kathleen Mulligan,
Viva Tai,
Michael Wen,
Artem Dyachenko,
Melissa E. Weinberg,
Xiaojuan Li,
Thomas Lang,
Carl Grünfeld,
JeanMarc Schwarz,
Morris Schambelan
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-2502
Subject(s) - insulin resistance , medicine , endocrinology , abdominal obesity , insulin like growth factor , insulin , human immunodeficiency virus (hiv) , obesity , abdominal fat , metabolism , carbohydrate metabolism , growth factor , distribution (mathematics) , biology , virology , metabolic syndrome , receptor , mathematical analysis , mathematics
HIV-infected patients on antiretroviral therapy are at increased risk for excess visceral adiposity and insulin resistance. Treatment with GH decreases visceral adiposity but worsens glucose metabolism. IGF-I, which mediates many of the effects of GH, improves insulin sensitivity in HIV-negative individuals.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom